- A new metabolite of Paricalcitol: stereoselective synthesis of (22Z)-isomer of 1α,25-dihydroxy-19-norvitamin D2
-
Stereoselective synthesis of (22Z)-isomer of Paricalcitol, an analog of 1,25-dihydroxyergocalciferol, an active form of vitamin D2 (Ergocalciferol) has been described. The two key critical synthetic steps involved are Julia–Lythgoe's Wittig–Hor
- Samala, Ramakrishna,Sharma, Somesh,Basu, Manas K.,Mukkanti,Porstmann, Frank
-
supporting information
p. 1309 - 1312
(2018/03/26)
-
- Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects
-
We have synthesized a novel vitamin D receptor agonist VS-105 ((1R,3R)-5-((E)-2-((3αS,7αS)-1-((R)-1-((S)-3-hydroxy-2, 3-dimethylbutoxy)ethyl)-7α-methyldihydro-1H-inden-4(2H,5H,6H,7H,7αH) -ylidene)ethylidene)-2-methylenecyclohexane-1,3-diol). Preparation o
- Chen, Barbara,Kawai, Megumi,Wu-Wong, J. Ruth
-
p. 5949 - 5952
(2013/10/22)
-
- Synthesis and crystallographic study of 1,25-dihydroxyergocalciferol analogs
-
The hybrid analogs of 1,25-dihydroxyergocalciferol (PRI-5201 and PRI-5202) were synthesized as potential anticancer agents using a convergent strategy. The analogs were designed by combining a 19-nor modification of the A-ring with the homologated and rig
- Pietraszek, Anita,Malińska, Maura,Chodyński, Michal,Krupa, Malgorzata,Krajewski, Krzysztof,Cmoch, Piotr,Wo?niak, Krzysztof,Kutner, Andrzej
-
p. 1003 - 1014
(2013/10/21)
-
- VITAMIN D RECEPTOR AGONISTS AND USES THEREOF
-
Disclosed is a compound of Formula (I), in which R1, R2, R3, R4, R5, R6, X, and a are defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition comprising a compound or salt therof of Formula (I) and a method of treating a disease which benefits from the modulation of the vitamin D receptor, such as a bone disorder, cardiovascular disease, a cardiovascular complication associated with renal disease, endothelial dysfunction, hyperparathyroidism, hypocalcemia, an immune disorder, left ventricular hypertrophy, a proliferative disease, proteinuria, renal disease, and thrombosis.
- -
-
Page/Page column 87
(2010/11/04)
-
- Vitamin D analogs for obesity prevention and treatment
-
Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and/or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D3 or 1α
- -
-
-